Table 3 Efficacy of oral moxidectin (3 μg/kg) in preventing the development of selected isolates of D. immitis
Adult D. immitis worm counts1 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
Study | D. immitis isolate | Treatment2 | Dosage (μg/kg) | Days of Tx | No. Dogs with worms | Worm count range | Geometric mean3 | % reduction | Isolate phenotype |
1 | Michigan | Placebo | NA | 0 | 8 of 8 | 18–32 | 24.4a | NA | |
1 | Michigan | Moxidectin | 3 | 0 | 0 of 8 | 0 | 0.0b | 100 | Susceptible |
2 | MP3 | Placebo | NA | 0 | 8 of 8 | 21–42 | 35.1a | NA | |
2 | MP3 | Moxidectin | 3 | 0 | 0 of 8 | 0 | 0.0b | 100 | Susceptible |
3 | ZoeKY | Placebo | NA | 0 | 6 of 6 | 16–36 | 26.2a | NA | |
3 | ZoeKY | Moxidectin | 3 | 0 | 0 of 6 | 0 | 0 b | 100 | Susceptible |
4 | GCFL | Placebo | NA | 0 | 3 of 3 | 21–35 | 28.4a | NA | |
4 | GCF | Moxidectin | 3 | 0 | 0 of 3 | 0 | 0b | 100 | Susceptible |
5 | ZoeAL | Placebo | NA | 0 | 6 of 6 | 26–47 | 33.0a | NA | |
5 | ZoeAL | Moxidectin | 3 | 0 | 0 of 6 | 0 | 0b | 100 | Susceptible |
6 | JYD-34 | Placebo | NA | 0, 30, 60 | 8 of 8 | 29–43 | 35.9a | NA | |
6 | JYD-34 | Moxidectin | 3 | 0 | 8 of 8 | 20–39 | 29.1b | 19.0 | Resistant |
6 | JYD-34 | Moxidectin | 3 | 0, 30, 60 | 8 of 8 | 7–36 | 20.0b | 44.4 | Resistant |
7 | ZoeMO | Placebo | NA | 0 | 6 of 6 | 15–32 | 21.2a | NA | |
7 | ZoeMO | Moxidectin | 3 | 0 | 6 of 6 | 2–7 | 5.5b | 82.7 | Resistant |
8 | ZoeLA | Placebo | NA | 0 | 6 of 6 | 22–38 | 32.2a | NA | |
8 | ZoeLA | Moxidectin | 3 | 0 | 6 of 6 | 11–26 | 14.8b | 54.0 | Resistant |
9 | AMAL | Placebo | NA | 0 | 3 of 3 | 43–48 | 45.0a | NA | |
9 | AMAL | Moxidectin | 3 | 0 | 3 of 3 | 12–25 | 17.3b | 61.6 | Resistant |